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1  | INTRODUC TION
Chronic pain is often treated with opioids, but other drug classes 
such as the serotonin- norepinephrine reuptake inhibitors (SNRIs) 
have also shown analgesic effects. The effects of opioids are medi-
ated by activation of opioid receptors, mainly present in supraspinal, 
spinal, and peripheral levels of the nervous system. SNRIs are 
thought to exert their effect primary on serotonergic and norad-
renergic pathways.1 Thus, different mechanisms may be involved in 
the antinociceptive effect of the two drug classes. Oxycodone is a 
mu- opioid receptor agonist, and venlafaxine is an SNRI (antidepres-
sant) with an analgesic effect. The antinociceptive mechanisms of 
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Summary
Aim: Different mechanisms may be involved in the antinociceptive effects of oxyco-
done (opioid) and venlafaxine (serotonin- norepinephrine reuptake inhibitor), and the 
aim of this study was to investigate the effect of these drugs on brain functional 
connectivity.
Methods: Resting state functional magnetic resonance imaging was acquired in 20 
healthy volunteers before and after a 5- day treatment with oxycodone, venlafaxine, 
or placebo in a randomized, double- blind, crossover study. Functional connectivity 
analyses were performed between four predefined seeds (dorsal anterior cingulate 
cortex, rostral anterior cingulate cortex, posterior insula, and prefrontal cortex), and 
the whole brain.
Results: The overall interpretation was that there were differences between the ef-
fects of oxycodone and venlafaxine on functional connectivity. Oxycodone mainly 
showed decreased functional connectivity between limbic structures and to supral-
imbic areas (all P < 0.05). Venlafaxine also showed decreased functional connectivity 
between limbic structures and to supralimbic areas, but increased functional con-
nectivity to structures in the midbrain and brain stem was also found (all P < 0.05).
Conclusions: Oxycodone and venlafaxine showed differential effects on resting- 
state functional connectivity as compared to placebo. This supports that the two 
drugs exert different mechanisms, and that the drugs in combination may exert addi-
tive effects and could potentially improve pain therapy.
K E Y W O R D S
functional connectivity, magnetic resonance imaging, opioid, resting state, serotonin-
norepinephrine reuptake inhibitor
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venlafaxine are not fully elucidated, but it has been suggested to be 
related to the opioidergic system.1-4
Functional magnetic resonance imaging (fMRI) has been widely 
used to study brain activity, and the interest of using fMRI to study 
the modulation of neuronal activation by drug administration is 
growing. Resting- state fMRI (RSfMRI) is one approach to investigate 
drug mechanisms in terms of functional connectivity between brain 
regions during resting state; however, limited studies on drug ef-
fects on functional connectivity exist5-7. Gorka et al investigated the 
effect of oxycodone on functional connectivity from two seeds of 
interest, the dorsal anterior cingulate cortex (dACC), and the rostral 
anterior cingulate cortex (rACC) and demonstrated that oxycodone 
decreased functional connectivity to insula.6
As oxycodone and potentially venlafaxine have impact on the 
opioidergic system, we hypothesized that oxycodone and venla-
faxine reveal both similar, but to some extent also different effect 
on functional connectivity. Recently we used magnetic resonance 
spectroscopy to show that oxycodone and venlafaxine decreased 
the concentration of the neurotransmitter glutamate in the anterior 
cingulate cortex, insula, and prefrontal cortex.8 As these regions 
are also rich in opioid receptors, they were selected for the current 
study.9-11 Accordingly, the aim of this study was to investigate the 
effect of oxycodone and venlafaxine treatment on functional con-
nectivity in these regions of interest in healthy volunteers as com-
pared to placebo.
2  | METHODS
Twenty healthy male subjects (mean age 24.6 ± 2.5 years) were 
MRI scanned in a randomized, double- blind, three- way crosso-
ver study. They were treated with oxycodone, venlafaxine, or pla-
cebo and scanned on day one (before each treatment) and after 
5 days of treatment. The “wash- out” periods between treatments 
were at least 1 week. The study was carried out at Department 
of Radiology, Aalborg University Hospital, Denmark and at Mech- 
Sense, Department of Gastroenterology and Hepatology, Aalborg 
University Hospital, Denmark.
2.1 | Experimental protocol
All subjects underwent a routine health screening conducted by a 
medical doctor to exclude subjects with any pain and nervous sys-
tem related conditions, and subjects with a history of abuse or men-
tal disorders were also excluded. Subjects gave written, informed 
consent before enrollment and could withdraw from the study at 
any time. Inclusion criteria were male, age between 20 and 35 years, 
normal medical examination, ability to read and understand Danish 
and of Scandinavian origin.
The study was approved by the local Ethics Committee (N- 
20130011) and the Danish Medicines Agency (201300017030) and 
monitored by the Good Clinical Practice unit at Aalborg and Aarhus 
University Hospitals, Denmark. The study was conducted according 
to the Declaration of Helsinki and registered with the European 
Clinical Trials Database (EudraCT 2013- 000170- 30).
2.2 | Drug administration
Oxycodone (10 mg extended release, “Accord,” Accord Healthcare, 
Salzburg, Austria), venlafaxine (37.5 mg extended release, “Stada,” 
Stada Nordic ApS, Herlev, Denmark), and placebo (8 mm tablets) were 
orally administered. Tablets were over- encapsulated in DBcaps®, 
Swed.orange, size AA, “Capsugel®, Basel, Switzerland.” Capsules 
were administered once on day 1 and day 5, and twice a day on 
day 2- 4 (8 doses in total with twelve hours in between). Medication 
was handled, packed, and delivered by Hospital Pharmacy, Central 
Denmark Region, Denmark.
2.3 | Brain imaging
Magnetic resonance imaging data were acquired on a 3T GE scan-
ner (GE Signa HDxt, General Electric, Milwaukee, WI, USA) with a 
standard eight- channel head coil. The head was fixed using foam 
pads. A high- resolution T1- weighted structural scan was acquired 
(TR/TE: 9.0 ms/3.6 ms, flip angle: 14°, field of view (FOV): 25 cm, 
matrix: 320 × 320, and voxel size: 0.8 × 0.8 × 1.0 mm). Resting- state 
fMRI was acquired for 6:32 minutes as 192 volumes of gradient echo 
planar images (TR/TE: 2000 ms/30 ms, flip angle: 90°, FOV: 24 cm, 
matrix: 64 × 64, and voxel size: 2.5 × 2.5 × 3.8 mm). Four dummy 
scans were acquired for all functional scans prior to scanning of the 
192 volumes. Volunteers were instructed to remain awake and to lie 
in the most relaxed position with closed eyes.
2.4 | Resting- state functional connectivity 
data analyses
The fMRI data were preprocessed and analyzed using SPM12 
(Wellcome Trust Centre for Neuroimaging, London, UK). Images 
were slice timing corrected, realigned to correct for head move-
ment, structural images and functional images were coregistered, 
segmented into CSF, white matter and gray matter, normalized to a 
standard brain in the MNI (Montreal Neurological Institute, Montreal, 
Canada), and smoothed (full width at half maximum = 8 mm). The 
functional connectivity (CONN) toolbox,12 www.nitrc.org/projects/
conn, was used for connectivity analyses. Effects of nuisance co-
variates, cerebrospinal fluid, white matter, and motion parameters 
(including the first derivative), obtained during realignment were 
regressed from the data. The data were band- pass filtered to 0.008- 
0.09 Hz. Seed- to- voxel first- level analyses for all subjects were 
performed by calculating the temporal correlation between blood- 
oxygen- level- dependent signals from four predefined seeds to all 
voxels in the brain. The predefined seeds were: (i) the dorsal anterior 
cingulate cortex (dACC) (10 mm sphere around center MNI coordi-
nates (0, 6, 40); (ii) rostral anterior cingulate cortex (rACC) (10 mm 
sphere around center MNI coordinates (0, 46, 2); (iii) right poste-
rior insula (insula) (10 mm sphere around center MNI coordinates 
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(37, −27, 12); and (iv) right prefrontal cortex (PFC) (10 mm sphere 
around center MNI coordinates (14, 48, 28)). The MarsBar toolbox 
was used to extract seeds.13 The second- level analyses were per-
formed in SPM12. Differences in functional connectivity across the 
three baselines (before treatments) were investigated for each seed 
using paired sample t tests. Treatment effects were investigated 
using paired sample t tests between treatment sessions (placebo vs 
oxycodone, placebo vs venlafaxine), and the directions of effects 
were investigated (placebo > oxycodone; placebo < oxycodone; 
placebo > venlafaxine; placebo < venlafaxine). We used a primary 
threshold (P < 0.005) and cluster- extent based thresholding with 
k > 220 voxels. The MNI coordinates (X, Y, Z) for the maximum t- 
value (obtained from the t tests) in each activated area were pre-
sented together with the number of voxels and the z- value.
3  | RESULTS
Due to logistic challenges, one subject missed an MRI scan before 
venlafaxine treatment, and another subject missed a scan after 
oxycodone treatment. Furthermore, one subject was excluded 
due to high level of movements (>2.5 mm and/or 2.5 degrees). 
Consequently, 18 subjects were included for analyses between 
baseline scans, 18 subjects were included for analyses of the oxy-
codone effects, and 19 subjects were included for analyses of the 
venlafaxine effects.
3.1 | Treatment effects on functional connectivity
To verify the changes in functional connectivity to be treatment re-
lated, functional connectivity of measurements before treatments 
were compared. No significant differences in functional connectiv-
ity of areas relevant for the treatment response (as reported below 
for oxycodone and venlafaxine treatment) were seen between the 
baseline scans. Differences in baseline connectivity were confined 
to the occipital cortex, lingual gyrus, intracalcarine cortex, mid-
dle temporal gyrus, parahippocampal gyrus, and temporal pole (all 
P < 0.05), see Table S1.
The effects of oxycodone and venlafaxine treatment on func-
tional connectivity from the predefined seeds (dACC, rACC, insula, 
and PFC) to other brain regions are presented in Tables 1-4, respec-
tively and in Figure 1. To provide an overview, the overall trends of 
the treatment effects are summarized in Table 5.
3.2 | Oxycodone
Significant decreased functional connectivity (compared to placebo) 
was found for oxycodone treatment (i) between dACC and insula and 
parietal regions, (ii) between rACC and frontal regions, (iii) between 
insula and operculum and parietal regions, and (iv) between PFC 
and posterior cingulate and parietal regions (all P < 0.05). Significant 
increased functional connectivity was found (i) between dACC and 
anterior cingulate regions, (ii) between rACC and frontal regions, 
and (iii) between PFC and anterior cingulate and parietal regions (all 
P < 0.05). Overall, oxycodone mostly affected functional connectiv-
ity in limbic and supralimbic regions.
3.3 | Venlafaxine
Significant decreased functional connectivity (compared to placebo) 
was found for venlafaxine treatment (i) between dACC and posterior 
cingulate, parietal regions, and frontal regions, (ii) between rACC and in-
sula/operculum and frontal regions, (iii) between insula and parietal re-
gions, and (iv) between PFC and insula/operculum and parietal regions 
(all P < 0.05). Increased functional connectivity was found (i) between 
dACC and frontal regions, rACC, and frontal regions and (ii) between 
Region name X Y Z Voxels Z- score Puncorr
Oxycodone<placebo
Superior parietal lobule, left −28 −48 76 908 4.21 <0.001
Supramarginal gyrus, right 64 −34 38 813 4.08 <0.001
Insula 42 2 2 325 3.32 0.010
Oxycodone > placebo
Precentral gyrus −4 −22 58 598 3.91 0.001
Anterior cingulate gyrus 2 40 18 245 3.69 0.021
Venlafaxine < placebo
Superior frontal gyrus, left −8 44 34 637 3.95 0.001
Supramarginal gyrus, left −68 −48 26 512 3.84 0.002
Middle frontal gyrus, left −52 26 40 311 3.72 0.010
Posterior cingulate gyrus 2 −24 38 278 3.66 0.014
Venlafaxine > placebo
Superior frontal gyrus, right 22 5 54 223 3.61 0.024
Oxycodone < placebo, decreased functional connectivity; Oxycodone > placebo, increased func-
tional connectivity, same nomenclature for venlafaxine.
TABLE  1 Functional connectivity 
between dACC and other voxels in the 
brain
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insula and thalamus and brain stem (all P < 0.05). Overall, venlafaxine 
mostly affected functional connectivity in the limbic system and in 
deeper structures (thalamus and brain stem).
4  | DISCUSSION
We investigated the effect of oxycodone and venlafaxine on cin-
gulate, insula, and prefrontal functional connectivity to other brain 
regions. In comparison with placebo, functional connectivity was 
affected by both active treatments and involved all the predefined 
brain areas. The effect of oxycodone on functional connectivity was 
more pronounced in the limbic and supralimbic system, whereas 
the effect of venlafaxine on functional connectivity was more pro-
nounced in the limbic system and in deeper structures (thalamus and 
brain stem).
4.1 | Drug effects on functional connectivity
Previous studies have shown MRI resting- state functional connec-
tivity to be useful to evaluate drug action on the central nervous sys-
tem.5,14,15 Oxycodone is a mu- opioid receptor agonist, and a number 
of previous studies have reported that cingulate, insula, and prefron-
tal cortex are rich in opioid receptors.9-11 ACC, especially, has high 
opioidergic binding potential, and it has previously been demon-
strated that oxycodone treatment reduced functional connectivity 
Region name X Y Z Voxels Z- score Puncorr
Oxycodone < placebo
Middle temporal gyrus, left −64 −8 −22 381 4.15 0.006
Frontal medial cortex, left 14 44 −6 544 4.02 0.002
Oxycodone > placebo
Middle frontal gyrus, left −18 12 36 767 4.28 <0.001
Middle frontal gyrus, right 22 4 40 791 3.80 <0.001
Venlafaxine < placebo
Insula, left −44 −22 2 1384 4.94 <0.001
Parietal operculum, right 58 −32 22 374 4.64 0.007
Insula, right 54 2 −8 1356 4.08 <0.001
Superior frontal gyrus, right 16 2 70 292 3.76 0.014
Frontal orbital gyrus/inferior 
frontal gyrus
44 30 −6 231 3.23 0.026
Venlafaxine > placebo
Cerebellum −26 −94 −38 480 4.47 0.003
Superior frontal gyrus 2 56 46 361 3.49 0.007
Lingual gyrus 0 −76 −2 432 3.34 0.004
TABLE  2 Functional connectivity 
between rACC and other voxels in the 
brain
Region name X Y Z Voxels Z- score Puncorr
Oxycodone < placebo
Opercular cortex, right 58 −10 12 1944 4.04 <0.001
Postcentral gyrus, left −40 −24 40 676 3.65 0.001
Superior temporal gyrus, right −70 −30 2 587 3.53 0.001
Precentral gyrus, left −40 −18 58 227 3.15 0.030
Oxycodone > placebo NS
Venlafaxine < placebo
Postcentral gyrus, left −52 −28 44 877 5.03 <0.001
Venlafaxine > placebo
Thalamus 6 −16 10 475 4.29 0.003
Cerebellum 24 −54 −48 549 3.68 0.001
Brain stem 8 −14 −18 225 3.60 0.026
Cerebellum 18 −86 −52 424 3.54 0.004
NS, nonsignificant.
TABLE  3 Functional connectivity 
between insula and other voxels in the 
brain
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between dACC/rACC and insula.6 In this study, we demonstrated 
that oxycodone decreased functional connectivity in the limbic 
system. In line with Gorka et al we found reduced functional con-
nectivity between dACC and insula for oxycodone treatment and 
furthermore functional connectivity was decreased between insula 
and opercular cortex. ACC and insula work together in the salience 
network and integrate interoceptive information with emotional 
salience and awareness.16,17 Moreover, ACC and insula are regions 
well known to be important in pain processing.18 Increased func-
tional connectivity between ACC and insula during rest has been 




−18 −50 8 379 4.10 0.004
Temporal occipital cortex, left −20 −52 −16 445 3.92 0.002
Postcentral gyrus, right 12 −44 78 260 3.84 0.014
Paracingulate gyrus 6 42 −10 256 3.54 0.015
Cerebellum 10 −40 −28 402 3.48 0.003
Oxycodone > placebo
Precentral gyrus, left −40 −6 46 1954 5.05 <0.001
Superior parietal gyrus, right 38 −48 48 361 4.39 0.005
Precentral gyrus, right 46 4 34 351 3.97 0.006
Middle temporal gyrus, left −64 −60 4 293 3.64 0.010
Superior parietal lobule, left −38 −54 50 270 3.60 0.013
Anterior cingulate/paracingulate −16 12 38 251 3.34 0.016
Venlafaxine < placebo
Opercular cortex, left −42 −10 18 276 3.55 0.016
Venlafaxine > placebo
Supramarginal gyrus, left −64 −44 44 248 3.36 0.021
TABLE  4 Functional connectivity 
between PFC and other voxels in the brain
F IGURE  1 Treatment effects on 
functional connectivity between 
preselected seeds (the dorsal anterior 
cingulate cortex (dACC), the rostral 
anterior cingulate cortex (rACC), the 
right posterior insula (insula) and the 
right prefrontal cortex (PFC)) and other 
voxels in the brain for oxycodone 
(left column) and venlafaxine (right 
column) as compared to placebo. Green: 
preselected seed; Blue: decreased 
functional connectivity as compared 
to placebo; Red: increased functional 
connectivity as compared to placebo. 
The presented results are cluster- extent 
based thresholded (k > 220) with primary 
threshold of P < 0.005. Note that the 
seeds of interest (green) are the same size 
(10 mm sphere) for all preselected seeds, 
and not visible in all slices as the selected 
slices focus on the brain regions with 
changes in connectivity
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demonstrated in chronic pain conditions,19,20 and in an acute pain 
model, we showed increased activity in ACC, insula, and thalamus in 
healthy volunteers, whereas morphine (mu- opioid receptor agonist) 
decreased activity in insula, ACC, and inferior parietal cortex.21 Even 
in absence of painful stimulation, we demonstrated in the present 
study that oxycodone decreased functional connectivity in these 
brain regions. Hence, we may infer that modulation of functional 
connectivity in these brain regions could be related to activation 
of opioid receptors and hence changed neuronal activity in these 
regions. Furthermore, in our recent magnetic resonance spectros-
copy study, decreased concentration of the neurotransmitter glu-
tamate was observed in response to oxycodone treatment (and a 
trend for venlafaxine treatment) in the insula, ACC, and prefrontal 
cortex.8 In addition to this, in two EEG source localization studies, 
which used the same cohort of healthy volunteers as this study, we 
showed frontal shift of cingulate activity in response to oxycodone 
treatment in the cingulate- operculum network underlying nocicep-
tive withdrawal reflex evoked potentials and an increase in cingu-
late activity coupled with a decrease in operculum activity,22 and we 
observed a decrease in insula and frontal gyrus activity underlying 
tonic pain following oxycodone treatment.23 It can also be proposed 
then, that the shifts and changes of activity seen in the previous 
surface EEG studies could be related to the changes in functional 
connectivity as observed in our present MRI study. We found both 
increased and decreased functional connectivity from cingulate to 
frontal regions. Increased functional connectivity between dACC 
and frontal regions has previously been shown in response to oxy-
codone treatment, and this has been suggested to reflect acutely 
increased cognitive control over subjective pain unpleasantness.6 As 
overall reduced functional connectivity was seen for all seeds of in-
terest to parietal regions, this may indicate an inhibition of neuronal 
activity, which may be central in inhibition of pain processing, when 
pain is present.
Venlafaxine is an antidepressant drug, which modulates the se-
rotonergic and noradrenergic pathways, and is believed to involve 
descending pain inhibitory systems.3 It is still not elucidated how 
this mechanism differentiates from opioidergic pathways, and a 
complex interaction between several neurotransmitter systems 
might be involved in the underlying mechanisms for the antinoci-
ceptive effects of venlafaxine. Similar to oxycodone, venlafaxine 
demonstrated decreased functional connectivity in the limbic sys-
tem. In particular, decreased functional connectivity was observed 
between rACC and insula, which may indicate the involvement of 
opioidergic pathways at least to some extent. Previous studies 
have proposed that venlafaxine improves attention, motor activity, 
and response time.24 To observe the effects of venlafaxine on the 
human motor cortex, a study using fMRI in combination with dif-
ferent motor tasks showed that one- week treatment improved the 
finger- tapping rate and increased the activations of contralateral 
primary sensorimotor cortex, contralateral premotor cortex, and 
contralateral supplementary motor area.25 On the other hand, the 
authors found the activation of the parietal cortices was decreased. 
Another study in duloxetine (SNRI) in healthy volunteers showed 
reduced functional connectivity between the medial prefrontal 
cortex and the lateral parietal cortex.26 We also found venlafaxine 
to reduce functional connectivity to parietal regions. Additionally, 
using the same cohort of healthy volunteers as in the present study, 
in our previous EEG study involving spinal and cortical evoked po-
tentials, we observed a decrease in latencies induced by venlafaxine 
treatment,27 and in an EEG study involving tonic pain, we observed 
a decrease in alpha activity induced by venlafaxine treatment, which 
was correlated to decrease in pain scores.23 The observed changes 
in the surface EEG could be related to changes in functional con-
nectivity observed in our present MRI study. Consequently, it could 
be speculated that these changes in functional connectivity to ven-
lafaxine treatment are centrally involved in the mechanisms of pain 
relief. Finally, we observed that venlafaxine increased functional 
connectivity from insula to thalamus and the brain stem. This in-
creased functional connectivity may present a part of the thalamic 
feedback loop of descending pain inhibition resulting in reduction 
of pain signaling. However, experiments involving pain are needed 
to verify this.
TABLE  5 Summary of the overall treatment effects (as compared to placebo) on functional connectivity between dACC, rACC, insula, 
and PFC cortex and relevant brain regions
dACC rACC Insula PFC




Cingulate regions Oxycodone ↑ (a) 
Venlafaxine ↓ (p)
Oxycodone ↓ (p) ↑ (a)










dACC, dorsal anterior cingulate cortex; rACC, rostral anterior cingulate cortex; PFC, right prefrontal cortex; ↓, decreased functional connectivity; ↑, 
increased functional connectivity; ↓↑, decreased and increased functional connectivity has been found within the region; (a), anterior region; (p), pos-
terior region.
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4.2 | Methodological considerations
In this study, we investigated the effect of oxycodone and venlafax-
ine on functional connectivity during resting state, and we demon-
strated drug induced changed functional connectivity. An important 
advantage of estimation of functional connectivity during rest, and 
not during task (eg, painful stimulation), is that the estimated effects 
are not confounded by, for example, anticipation, performance, or 
other task- induced confounders. On the other hand, as this study did 
not include pain models or subjects with chronic pain, the analgesic 
effects of the drugs cannot be distinguished and further research is 
needed to address that aspect.
As we used a hypothesis- driven seed- based method and a 
relatively small sample size, we used a liberal primary thresh-
old (P < 0.005)12 followed by a cluster- extent based thresholding 
method. An advantage of using cluster- extent based thresholding is 
higher sensitivity in identifying significant regions, but low spatial 
specificity is a disadvantage, and accurate inferences about the true 
activation are difficult.28
The treatment period of 5 days for venlafaxine may not be suf-
ficient to reach the maximal effect in the brain and should optimally 
have been longer (ie, at least 2 weeks).29 However, this study was 
conducted in healthy subjects, and it was not feasible to treat for 
longer than 5 days for ethical reasons. Moreover, effects of ven-
lafaxine on the pain system have been observed already after few 
days of treatment.30 Another study found that a single dose of a 
serotonin reuptake inhibitor dramatically altered functional connec-
tivity in the human brain.31 Hence, although the longer treatment is 
desired for the maximal clinical effect, we believe that the five- day 
treatment in this study was long enough to observe relevant changes 
in the central nervous system.
5  | CONCLUSIONS
In this placebo- controlled study in healthy subjects, the effects of 
oxycodone and venlafaxine treatment on functional connectivity 
were investigated. Functional connectivity was affected by both 
treatments involving all the investigated brain regions. Differential 
effects of oxycodone and venlafaxine on resting- state functional 
connectivity were found supporting that venlafaxine exerts differ-
ent mechanisms compared to oxycodone. Thus, future drug devel-
opment for pain treatment could be improved as both drugs can be 
used as monotherapy, but also in combination with different mecha-
nisms can be targeted. However, future studies involving pain are 
needed to support this idea.
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